-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

Benzinga·10/14/2026 12:59:02
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.